3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Meningioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Glioblastoma
1
Estrogen Receptor Positive Breast Cancer
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Solid Malignancies
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Rituximab
187
Cyclophosphamide
174
Etoposide
94
Peripheral Blood Stem Cell Transplantation
90
Vincristine
89
Prednisone
80
Doxorubicin
79
Filgrastim
75
fludarabine phosphate
60
Radiotherapy
56
Mycophenolic Acid
41
Melphalan
41
Cytarabine
41
Busulfan
40
Cyclosporine
39
Methotrexate
37
Whole-Body Irradiation
36
Tacrolimus
35
Carmustine
34
Ifosfamide
28
Lenalidomide
27
Granulocyte Colony-Stimulating Factor
27
Antilymphocyte Serum
27
Gemcitabine
25
Carboplatin
25
Methylprednisolone
24
ibritumomab tiuxetan
23
Bortezomib
22
Dexamethasone
21
ibrutinib
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Large B-Cell, Diffuse
×
vistusertib
×
Clear all
NCT02752204
2020-11-05
TORCH
University of Birmingham
Phase 2
Completed
36 enrolled